On the heels of a move to reduce its viral vector manufacturing workforce, Thermo Fisher is beefing up its biologics ...

Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...

Blood test maker Grail has recruited ‘Grey’s Anatomy’ star Kate Walsh to join a campaign focused on encouraging Gen Xers to ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound.

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen ...

HHS secretary Robert F. Kennedy Jr. has been on the receiving end of two heated letters from lawmakers outlining the threats ...

Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...

In a bid to break into the CDMO business at one of its most lucrative angles, India's Granules is snapping up Swiss contract ...

Author:  Brad Chapman, Head of U.S. Epilepsy and Rare Syndromes, UCB | Hear from UCB’s Brad Chapman on the importance of ...

As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...